Marinus Pharmaceuticals Appoints Charles Austin to Board

RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Charles Austin to its Board of Directors.

“Chuck is a recognized leader in the pharmaceutical and medical device industries,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “As a board member, we are excited to draw from his tremendous manufacturing and biopharma expertise as Marinus continues to grow and develop as an organization.”

With more than 25 years of experience in the life sciences sector, Mr. Austin has held numerous roles in supply chain operations, research and development, and engineering throughout his career with Johnson & Johnson. Prior to his appointment to Marinus’ Board of Directors, Mr. Austin served as Corporate Vice President, Global Supply Chain at Johnson & Johnson, where he was a member of the Johnson & Johnson Management Committee and was responsible for all manufacturing, logistics, quality, compliance, direct procurement, environmental, health and safety, and engineering and real estate for the corporation.

As Company Group Chairman of Ethicon Surgical Care – a Johnson & Johnson Company – Mr. Austin helped combine four separate operating units, re-engineer a global commercial model, and return the overall franchise to growth.

“We are delighted that Chuck will be joining the board, and we feel confident that his successful commercial, as well as operational background will bring a complementary skill set to our current board,” said Nicole Vitullo, Director, Chairman of the Board at Marinus. “We believe that he will be instrumental in advancing the company’s strategy as we approach key milestones in our epilepsy programs.”

Mr. Austin obtained a Bachelor of Science in Engineering from the United States Military Academy, West Point, New York, and served in the United States Army for over nine years. He currently serves on multiple boards in the medical and consumer spaces and is a principal in JK Advisors, a San Diego based firm focused on the medical space.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of treatments in rare epilepsy and neuropsychiatric disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit Please follow us on Twitter: @MarinusPharma.